333 related articles for article (PubMed ID: 29844255)
1. A Half-Century History of Applications of Antisense Oligonucleotides in Medicine, Agriculture and Forestry: We Should Continue the Journey.
Oberemok VV; Laikova KV; Repetskaya AI; Kenyo IM; Gorlov MV; Kasich IN; Krasnodubets AM; Gal'chinsky NV; Fomochkina II; Zaitsev AS; Bekirova VV; Seidosmanova EE; Dydik KI; Meshcheryakova AO; Nazarov SA; Smagliy NN; Chelengerova EL; Kulanova AA; Deri K; Subbotkin MV; Useinov RZ; Shumskykh MN; Kubyshkin AV
Molecules; 2018 May; 23(6):. PubMed ID: 29844255
[TBL] [Abstract][Full Text] [Related]
2. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
3. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
4. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
5. Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides.
Ezzat K; Aoki Y; Koo T; McClorey G; Benner L; Coenen-Stass A; O'Donovan L; Lehto T; Garcia-Guerra A; Nordin J; Saleh AF; Behlke M; Morris J; Goyenvalle A; Dugovic B; Leumann C; Gordon S; Gait MJ; El-Andaloussi S; Wood MJ
Nano Lett; 2015 Jul; 15(7):4364-73. PubMed ID: 26042553
[TBL] [Abstract][Full Text] [Related]
6. New developments in exon skipping and splice modulation therapies for neuromuscular diseases.
Touznik A; Lee JJ; Yokota T
Expert Opin Biol Ther; 2014 Jun; 14(6):809-19. PubMed ID: 24620745
[TBL] [Abstract][Full Text] [Related]
7. Transcript-Targeted Therapy Based on RNA Interference and Antisense Oligonucleotides: Current Applications and Novel Molecular Targets.
Barresi V; Musmeci C; Rinaldi A; Condorelli DF
Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012138
[TBL] [Abstract][Full Text] [Related]
8. Transfection of normal primary human skeletal myoblasts with p21 and p57 antisense oligonucleotides to improve their proliferation: a first step towards an alternative molecular therapy approach of Duchenne muscular dystrophy.
Endesfelder S; Bucher S; Kliche A; Reszka R; Speer A
J Mol Med (Berl); 2003 Jun; 81(6):355-62. PubMed ID: 12732930
[TBL] [Abstract][Full Text] [Related]
9. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for Duchenne muscular dystrophy.
Falzarano MS; Passarelli C; Ferlini A
Nucleic Acid Ther; 2014 Feb; 24(1):87-100. PubMed ID: 24506782
[TBL] [Abstract][Full Text] [Related]
10. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
Hanson B; Wood MJA; Roberts TC
RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
[TBL] [Abstract][Full Text] [Related]
11. Splicing therapy for neuromuscular disease.
Douglas AG; Wood MJ
Mol Cell Neurosci; 2013 Sep; 56():169-85. PubMed ID: 23631896
[TBL] [Abstract][Full Text] [Related]
12. Knocking Down Long Noncoding RNAs Using Antisense Oligonucleotide Gapmers.
Maruyama R; Yokota T
Methods Mol Biol; 2020; 2176():49-56. PubMed ID: 32865781
[TBL] [Abstract][Full Text] [Related]
13. Antisense oligonucleotides delivered to the mouse CNS ameliorate symptoms of severe spinal muscular atrophy.
Passini MA; Bu J; Richards AM; Kinnecom C; Sardi SP; Stanek LM; Hua Y; Rigo F; Matson J; Hung G; Kaye EM; Shihabuddin LS; Krainer AR; Bennett CF; Cheng SH
Sci Transl Med; 2011 Mar; 3(72):72ra18. PubMed ID: 21368223
[TBL] [Abstract][Full Text] [Related]
14. Antisense-mediated exon skipping: taking advantage of a trick from Mother Nature to treat rare genetic diseases.
Veltrop M; Aartsma-Rus A
Exp Cell Res; 2014 Jul; 325(1):50-5. PubMed ID: 24486759
[TBL] [Abstract][Full Text] [Related]
15. Precision Medicine through Antisense Oligonucleotide-Mediated Exon Skipping.
Li D; Mastaglia FL; Fletcher S; Wilton SD
Trends Pharmacol Sci; 2018 Nov; 39(11):982-994. PubMed ID: 30282590
[TBL] [Abstract][Full Text] [Related]
16. Better living through peptide-conjugated chemistry: next-generation antisense oligonucleotides.
McNally EM; Leverson BD
J Clin Invest; 2019 Nov; 129(11):4570-4571. PubMed ID: 31566581
[TBL] [Abstract][Full Text] [Related]
17. [Antisense therapies for neurological diseases].
Pulst SM
Nervenarzt; 2019 Aug; 90(8):781-786. PubMed ID: 31165208
[TBL] [Abstract][Full Text] [Related]
18. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes.
Pires VB; Simões R; Mamchaoui K; Carvalho C; Carmo-Fonseca M
PLoS One; 2017; 12(7):e0181065. PubMed ID: 28742140
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M; Badawi M; Abulrob A
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
[TBL] [Abstract][Full Text] [Related]
20. Translational development of splice-modifying antisense oligomers.
Fletcher S; Bellgard MI; Price L; Akkari AP; Wilton SD
Expert Opin Biol Ther; 2017 Jan; 17(1):15-30. PubMed ID: 27805416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]